Literature DB >> 28002724

Too Much of a Good Thing? Chronic IFN Fuels Resistance to Cancer Immunotherapy.

James L Reading1, Sergio A Quezada2.   

Abstract

Immune checkpoint blockade (ICB) is revolutionizing cancer medicine, yet the molecular basis of resistance remains unclear. In a recent issue of Cell, Benci et al. (2016) demonstrate that sustained interferon signaling is central to the development of PD-L1-dependent and -independent resistance to ICB.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 28002724     DOI： 10.1016/j.immuni.2016.12.004

Source DB:  PubMed          Journal:  Immunity        ISSN： 1074-7613            Impact factor:   31.745


  3 in total

1.  Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors.

Authors:  Martin H Pedersen; Brian L Hood; Hans Christian Beck; Thomas P Conrads; Henrik J Ditzel; Rikke Leth-Larsen
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

2.  Circulating immune cell phenotype dynamics reflect the strength of tumor-immune cell interactions in patients during immunotherapy.

Authors:  Jason I Griffiths; Pierre Wallet; Lance T Pflieger; David Stenehjem; Xuan Liu; Patrick A Cosgrove; Neena A Leggett; Jasmine A McQuerry; Gajendra Shrestha; Maura Rossetti; Gemalene Sunga; Philip J Moos; Frederick R Adler; Jeffrey T Chang; Sunil Sharma; Andrea H Bild
Journal:  Proc Natl Acad Sci U S A       Date:  2020-06-22       Impact factor: 11.205

3.  Regulating Glucose Metabolism with Prodrug Nanoparticles for Promoting Photoimmunotherapy of Pancreatic Cancer.

Authors:  Fang Sun; Qiurong Zhu; Tianliang Li; Madiha Saeed; Zhiai Xu; Feisheng Zhong; Rundi Song; Manxiu Huai; Mingyue Zheng; Cen Xie; Leiming Xu; Haijun Yu
Journal:  Adv Sci (Weinh)       Date:  2021-01-04       Impact factor: 16.806
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.